Data-Driven Improvements in Healthcare: Inovalon Holdings Inc.

Inovalon is a leading technology company providing cloud-based platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry. Through the Inovalon ONE™ Platform, Inovalon brings to the marketplace a national-scale capability to interconnect with the healthcare ecosystem on massive scale, aggregate and analyze data in petabyte volumes to arrive at sophisticated insights in real-time, drive impact wherever it is analytically identified best to intervene, and intuitively visualize data and information to inform business strategy and execution.

Leveraging its platform, unparalleled proprietary data sets, and industry-leading subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem. Providing technology that supports nearly 500 healthcare organizations, Inovalon’s platforms are informed by data pertaining to more than 932,000 physicians, more than 455,000 clinical facilities, and 240 million Americans.

Tit-Bits about the Company

Inovalon Holdings, Inc., a technology company headquartered in Bowie, Maryland was incorporated on September 11, 2014. The Company combines cloud-based data analytics and data-driven intervention platforms to provide services for health plans, hospitals, physicians, patients, pharmaceutical companies and researchers.

The Company operates through developing cloud-based data analytics and data-driven intervention platforms segment and provides related services to its clients. The Company’s datasets, integration technologies, predictive analytics and subject matter expertise allow the Company to provide platforms. Its analytics platforms identify gaps in care, quality, data integrity and financial performance in its clients’ datasets.

Transforming Health Industry

The entirety of the healthcare ecosystem is undergoing a massive transformation driven by the shift from volume-based to value-based forces. From healthcare services to diagnostics, devices, and pharmaceuticals, the need to deliver and improve value is impacting all segments of healthcare.

The Company’s data analytics and intervention platforms consist of four primary components: data integration, analytics, intervention platforms and business processing. The Company integrates data into its systems through its extract, transform, load (ETL) tools and processes.

The Company’s system manages the process of defining and configuring industry data feeds from its clients and partners, such as electronic health records (EHR), laboratory, pharmacy, patient reported, claims, paper-based medical records, biometric and hospital data feeds respectively; manages the data processing workflow, and monitors the ongoing provision and quality of data through the application of data integrity checks. In addition, to being maintained and tagged within client-specific data lakes, data the Company receives in the course of providing its services are statistically de-identified and stored in its MORE2 Registry.

The MORE2 Registry includes information about demographics, enrolment, diagnoses, procedures, pharmacy, laboratory results and deep medical record clinical data, and presents a representative mix of commercial, HIX Marketplace, Medicare Advantage and managed Medicaid care plan patients. The Company’s data-driven intervention platforms are toolsets and services that enable its clients to take the insights derived from its analytics and implement solutions at the patient and provider level. The Company’s business processing toolsets are made up of business intelligence system and data warehousing to provide data insight, reporting and benchmarking to support multiple client business needs, such as government-mandated data filings, financial planning, and compliance requirements.

iPort is its data integration and management process toolset. Its Predictive Clinical Insight System (PCIS) identifies the diagnoses and comorbidities that may exist for a patient but which are incompletely or improperly reflected within the clinical profile of the patient as known to the patient’s health plan. The PCIS system is designed to evaluate patients with undocumented conditions, worsening conditions and uncoded conditions that are important for the ongoing management of the patient. Its Quality Spectrum Insights Suite (QSI, QSFD, and QSCL) toolsets provide run-time engine tools for the design, development, and deployment of a set of healthcare data analytics across the spectrum of clinical and quality outcomes, healthcare utilization, spending patterns, provider and network performance and patient risk profiles.

Inovalon’s modular platforms leverage unparalleled proprietary data sets, advanced analytics, and data-driven intervention capabilities to assess and improve clinical & quality outcomes, utilization efficiency, and financial performance. Payors, providers, pharma/life sciences, specialty pharmacy, and device manufacturers – all share the same need for data-driven insights to help drive meaningful business impact and improve care.

The Leader behind the Behemoth

Keith R. Dunleavy, M.D., Chief Executive Officer and Chairman of the Board:

Dr. Dunleavy has served as Inovalon’s Chief Executive Officer since his organization of the company’s predecessor companies in 1998, as Chairman of the board of directors since the creation of the board in 2006, and as President from the Company’s foundation until May of 2014. Dr. Dunleavy is responsible for the overall execution of the company’s business plan, strategic relationships, and the identification and realization of company product strategy and vision.

Dr. Dunleavy received a Bachelor’s degree in Biology modified with Engineering with High Honors from Dartmouth College where his studies and work focused upon the neurosciences, computer sciences and electrical engineering with his honors thesis focused on the computer simulation of artificial human cerebellar functional units. Dr. Dunleavy earned his doctorate in medicine from Harvard Medical School, completed his medical residency at The Johns Hopkins Hospital in Baltimore, Maryland, practiced and was Board Certified in Internal Medicine.

“Turning Data into Insight, and Insight into Action”